GRACE
J

The CheckMate 816 Trial: The Success of Neoadjuvant NSCLC Therapies

By GRACE FEATURING Julia Rotow
By GRACE FEATURING Julia Rotow
1,542 views
January 26, 2023
2 Comments
Login to view comments. Click here to Login

Featured Video

09:36
Johnson & Johnson

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Feat. J. Heymach, M. Das

Featured Video

08:44
Johnson & Johnson

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira

Related Content

AUTOPLAY
08:49
David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

35:40
Balazs Halmos

Year in Review: Lung Cancer

17:20
Total Health

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Feat. J. Porter
57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
27:04
Fengting Yan

Cancer Screening Molecular Tools

18:47
Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
36:14
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

Feat. B. Halmos
02:41
GRACE

Staging Disease: How Oncologists Stage NSCLC

Feat. I. Dagogo-Jack, M. Das, C. Jeffrey Yang
16:10
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

Feat. L. Raez
29:25
Young Chae

Hyperprogression in Cancer Treated With Immunotherapy

07:43
Yale Cancer Center

2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertini…

Feat. P. Janne
17:34
ecancer

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

Feat. L. Raez
25:35
Total Health

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Feat. S. Kazmi
16:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

Feat. V. Subbiah
14:49
Vivek Subbiah

Year in Review: Precision Medicine

13:19
IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez
26:21
Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang
30:27
Insights from 2023 ESMO Annual Meeting

Perioperative Immunotherapy Strategies in Resectable NSCLC After ESM…

Feat. G. Mountzios
19:33
ecancer

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

Feat. E. Felip, A. Spira, A. Passaro, A. Addeo